Edition:
United States

Enzo Biochem Inc (ENZ.N)

ENZ.N on New York Stock Exchange

4.91USD
17 Jul 2018
Change (% chg)

$0.01 (+0.20%)
Prev Close
$4.90
Open
$4.90
Day's High
$5.02
Day's Low
$4.90
Volume
15,160
Avg. Vol
51,481
52-wk High
$11.99
52-wk Low
$4.86

Latest Key Developments (Source: Significant Developments)

Enzo Biochem Q3 Non-Gaap Loss Per Share $0.06
Monday, 11 Jun 2018 04:10pm EDT 

June 11 (Reuters) - Enzo Biochem Inc ::ENZO BIOCHEM REPORTS THIRD QUARTER RESULTS.Q3 NON-GAAP LOSS PER SHARE $0.06.TOTAL REVENUES IN QUARTER AMOUNTED TO $25.6 MILLION OR 5% LOWER THAN PRIOR YEAR.TOTAL CASH AND CASH EQUIVALENTS AT APRIL 30, 2018 WERE $62.6 MILLION COMPARED TO $64.2 MILLION AT JULY 31, 2017.  Full Article

Enzo Biochem Reports Q2 Adjusted Loss Per Share $0.04
Monday, 12 Mar 2018 04:05pm EDT 

March 12 (Reuters) - Enzo Biochem Inc ::ENZO BIOCHEM REPORTS SECOND QUARTER AND FIRST HALF RESULTS.Q2 ADJUSTED LOSS PER SHARE $0.04.Q2 REVENUE ROSE 3 PERCENT TO $27 MILLION.QTRLY LOSS PER SHARE $0.02.  Full Article

Enzo Biochem Q1 Non-GAAP Loss Per Share $0.01
Thursday, 7 Dec 2017 04:10pm EST 

Dec 7 (Reuters) - Enzo Biochem Inc ::ENZO BIOCHEM REPORTS IMPROVED FIRST QUARTER RESULTS.Q1 NON-GAAP LOSS PER SHARE $0.01.Q1 REVENUE $27.7 MILLION VERSUS $26.3 MILLION.  Full Article

‍Enzo Biochem announces NYS department of health's approval of a new women's health infectious disease panel​
Monday, 23 Oct 2017 08:30am EDT 

Oct 23 (Reuters) - Enzo Biochem Inc ::‍Enzo Biochem announces NYS department of health's approval of a new women's health infectious disease panel​.  Full Article

BRIEF-Enzo Biochem Q4 non-gaap net income of $0.00 per share (Sept 27)
Thursday, 28 Sep 2017 11:02am EDT 

Corrects headline and third bullet to Q4 non-gaap net income of $0.00/share from non-gaap loss of $0.04/share:Enzo Biochem reports increase in revenues and profitable fourth quarter.Q4 revenue $28.2 million versus $26.6 million.Q4 non-gaap net income per share $0.00.  Full Article

Enzo Biochem Q4 non-gaap loss per share $0.04
Wednesday, 27 Sep 2017 04:05pm EDT 

Sept 27 (Reuters) - Enzo Biochem Inc :Enzo Biochem reports increase in revenues and profitable fourth quarter.Q4 revenue $28.2 million versus $26.6 million.Q4 non-gaap loss per share $0.04.  Full Article

Enzo Biochem files for mixed shelf of up to $150 million ‍​
Friday, 1 Sep 2017 04:43pm EDT 

Sept 1 (Reuters) - Enzo Biochem Inc :Files for mixed shelf of up to $150 million - SEC filing ‍​.  Full Article

Enzo Biochem says federal judge in a U.S. Court has entered an order in action entitled Enzo Life Sciences v. Abbott Laboratories ​
Wednesday, 16 Aug 2017 06:18am EDT 

Aug 16 (Reuters) - Enzo Biochem Inc ::Enzo Biochem says ‍a federal judge in a U.S. Court has entered an order in action entitled Enzo Life Sciences, Inc. v. Abbott Laboratories - sec filing​.U.S. Court's order ‍denies summary judgment that U.S. Patent no. 8,097,405 is invalid for lack of written description.‍U.S. Court's order also granted summary judgment that U.S. Patent no. 8,097,405​ is invalid for lack of enablement.‍Enzo "disagrees" with court's decision, and is exploring options for review of decision​.  Full Article

Enzo Biochem says Q3 revenue up 2 pct to $27.1 mln
Thursday, 8 Jun 2017 04:10pm EDT 

June 8 (Reuters) - Enzo Biochem Inc :Q3 revenue rose 2 percent to $27.1 million.Q3 GAAP earnings per share $0.00.Enzo Biochem Inc qtrly total revenues increased to $27.1 million, a 2% increase.  Full Article

Enzo Biochem announces NY state health department approval of New Women’S Health Diagnostics
Thursday, 8 Jun 2017 04:00pm EDT 

June 8 (Reuters) - Enzo Biochem Inc :Enzo Biochem announces New York State Health Department approval of new Women’s Health Diagnostics.Approval for real-time PCR-based method for detection of neisseria gonorrhoeae, chlamydia trachomatis, trichomonas vaginalis in swab specimens.  Full Article

BRIEF-Enzo Biochem Says Patent Trial And Appeal Board Has Denied A Petition Filed By Hologic For Inter Partes Review

* ENZO BIOCHEM INC - PATENT TRIAL AND APPEAL BOARD HAS DENIED A PETITION FILED BY HOLOGIC FOR INTER PARTES REVIEW Source text for Eikon: Further company coverage: